Systemic Oxidative Stress, As Measured by Urinary Allantoin and F(2)-isoprostanes, is Not Increased in Down Syndrome

Overview

Journal Ann Epidemiol

Publisher Elsevier

Specialty Public Health

Date 2012 Oct 16

PMID 23063134

Citations 5

Authors

Adviye A Tolun

Peter M Scarbrough

Haoyue Zhang

Jane-Ann McKillop

Frances Wang

Priya S Kishnani

David S Millington

Sarah P Young

Dora Ilyasova

Affiliations

Soon will be listed here.

Abstract

Purpose: Oxidative stress has been implicated in Down syndrome (DS) pathology. This study compares DS individuals and controls on their urinary levels of allantoin and 2,3-dinor-iPF2α-III; these biomarkers have been previously validated in a clinical model of oxidative stress.

Methods: Urine samples were collected from 48 individuals with DS and 130 controls. Biomarkers were assayed by ultraperformance liquid chromatography-tandem mass spectrometry, normalized by urinary creatinine concentration.

Results: After adjusting for age and gender, mean allantoin levels were lower among DS individuals versus controls (P = .04). The adjusted mean levels of 2,3-dinor-iPF2α-III were similar in DS individuals and controls (P = .7).

Conclusions: Our results do not support the hypothesis that DS individuals have chronic systemic oxidative stress.

Citing Articles

Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.

Jacob C, Tollenaere M, Kachar H, Potier M, De Deyn P, Van Dam D Heliyon. 2025; 11(1):e41445.

PMID: 39850411 PMC: 11755057. DOI: 10.1016/j.heliyon.2024.e41445.

Systemic F-Isoprostane Levels in Predisposition to Obesity and Type 2 Diabetes: Emphasis on Racial Differences.

Ilyasova D, Wong B, Waterstone A, Kinev A, Okosun I Divers Equal Health Care. 2020; 14(2):91-101.

PMID: 32523692 PMC: 7286608. DOI: 10.21767/2049-5471.100098.

Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Barone E, Arena A, Head E, Butterfield D, Perluigi M Free Radic Biol Med. 2017; 114:84-93.

PMID: 28705658 PMC: 5748256. DOI: 10.1016/j.freeradbiomed.2017.07.009.

African Ancestry Gradient Is Associated with Lower Systemic F-Isoprostane Levels.

Annor F, Goodman M, Thyagarajan B, Okosun I, Doumatey A, Gower B Oxid Med Cell Longev. 2017; 2017:8319176.

PMID: 28250893 PMC: 5307136. DOI: 10.1155/2017/8319176.

Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.

Butterfield D, Di Domenico F, Swomley A, Head E, Perluigi M Biochem J. 2014; 463(2):177-89.

PMID: 25242166 PMC: 4686233. DOI: 10.1042/BJ20140772.

References

Roizen N . Complementary and alternative therapies for Down syndrome. Ment Retard Dev Disabil Res Rev. 2005; 11(2):149-55. DOI: 10.1002/mrdd.20063. View

Tamura S, Tsukahara H, Ueno M, Maeda M, Kawakami H, Sekine K . Evaluation of a urinary multi-parameter biomarker set for oxidative stress in children, adolescents and young adults. Free Radic Res. 2006; 40(11):1198-205. DOI: 10.1080/10715760600895191. View

Busciglio J, Yankner B . Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature. 1995; 378(6559):776-9. DOI: 10.1038/378776a0. View

An Y, Young S, Kishnani P, Millington D, Amalfitano A, Corz D . Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab. 2005; 85(4):247-54. DOI: 10.1016/j.ymgme.2005.03.010. View

Zhang H, Ilyasova D, Sztaray J, Young S, Wang F, Millington D . Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. Anal Biochem. 2009; 399(2):302-4. PMC: 2853187. DOI: 10.1016/j.ab.2009.12.024. View

Ilyasova D, Wang F, Spasojevic I, Base K, DAgostino Jr R, Wagenknecht L . Urinary F2-isoprostanes, obesity, and weight gain in the IRAS cohort. Obesity (Silver Spring). 2011; 20(9):1915-21. PMC: 4111086. DOI: 10.1038/oby.2011.292. View

Kauffman L, Sokol R, Jones R, Awad J, Rewers M, Norris J . Urinary F2-isoprostanes in young healthy children at risk for type 1 diabetes mellitus. Free Radic Biol Med. 2003; 35(6):551-7. DOI: 10.1016/s0891-5849(03)00333-2. View

Campos C, Guzman R, Lopez-Fernandez E, Casado A . Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome. Biochim Biophys Acta. 2011; 1812(7):760-8. DOI: 10.1016/j.bbadis.2011.03.013. View

Tolun A, Zhang H, Ilyasova D, Sztaray J, Young S, Millington D . Allantoin in human urine quantified by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Biochem. 2010; 402(2):191-3. PMC: 3595192. DOI: 10.1016/j.ab.2010.03.033. View

10.

Roizen N, Patterson D . Down's syndrome. Lancet. 2003; 361(9365):1281-9. DOI: 10.1016/S0140-6736(03)12987-X. View

11.

Ani C, Grantham-McGregor S, Muller D . Nutritional supplementation in Down syndrome: theoretical considerations and current status. Dev Med Child Neurol. 2001; 42(3):207-13. DOI: 10.1017/s0012162200000359. View

12.

Heller J, Spiridigliozzi G, Crissman B, Sullivan-Saarela J, Li J, Kishnani P . Clinical trials in children with Down syndrome: issues from a cognitive research perspective. Am J Med Genet C Semin Med Genet. 2006; 142C(3):187-95. DOI: 10.1002/ajmg.c.30103. View

13.

Ilyasova D, Spasojevic I, Wang F, Tolun A, Base K, Young S . Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev. 2010; 19(6):1506-10. PMC: 2883001. DOI: 10.1158/1055-9965.EPI-10-0211. View

14.

Zitnanova I, Korytar P, Sobotova H, Horakova L, Sustrova M, Pueschel S . Markers of oxidative stress in children with Down syndrome. Clin Chem Lab Med. 2006; 44(3):306-10. DOI: 10.1515/CCLM.2006.053. View

15.

Zana M, Szecsenyi A, Czibula A, Bjelik A, Juhasz A, Rimanoczy A . Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem Biophys Res Commun. 2006; 345(2):726-33. DOI: 10.1016/j.bbrc.2006.04.167. View

16.

Pratico D, Iuliano L, Amerio G, Tang L, Rokach J, Sabatino G . Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol. 2000; 48(5):795-8. View

17.

Campos C, Guzman R, Lopez-Fernandez E, Casado A . Evaluation of urinary biomarkers of oxidative/nitrosative stress in children with Down syndrome. Life Sci. 2011; 89(17-18):655-61. DOI: 10.1016/j.lfs.2011.08.006. View

18.

Salman M . Systematic review of the effect of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome. Eur J Paediatr Neurol. 2002; 6(4):213-9. DOI: 10.1053/ejpn.2002.0596. View

19.

Young S, Zhang H, Corzo D, Thurberg B, Bali D, Kishnani P . Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med. 2009; 11(7):536-41. DOI: 10.1097/GIM.0b013e3181a87867. View

20.

de Haan J, Wolvetang E, Cristiano F, Iannello R, Bladier C, Kelner M . Reactive oxygen species and their contribution to pathology in Down syndrome. Adv Pharmacol. 1997; 38:379-402. DOI: 10.1016/s1054-3589(08)60992-8. View